Clotrimazole vaginal tablet,
does it really help with Clinical and mycological cure of uncomplicated vulvovaginal candidiasis?
research showsClotrimazole vaginal tablets are rated B because they directly improve clinical and mycological cure of uncomplicated vulvovaginal candidiasis. The placebo-controlled trial was small, but the effect separation was large: nine of ten evaluable participants receiving a single 500-mg tablet were cured versus none of 13 receiving placebo. A 103-participant double-blind trial found early clinical and mycological clearance rates of 90% with one 500-mg dose and 89% with a three-day 100-mg regimen, and later active-controlled studies confirmed cure. The pivotal placebo evidence is very small and old, however, and most modern evidence is active-controlled or noninferiority-based, supporting B with 68 points. Local irritation, use during pregnancy, diagnostic error in self-treatment, and separate evaluation of recurrent or complicated infection remain safety matters.
ads claimMarketing can imply that any itching is candidiasis and one treatment cures recurrent or complicated disease. The best-fitting evidence concerns short-term clinical and mycological cure of confirmed uncomplicated Candida infection; recurrent or non-albicans disease may require a different diagnosis and regimen.
Useful facts when choosing a product
- Clotrimazole vaginal products use different regimens, including multidose 100-mg courses and a single 500-mg tablet, so the exact package instructions and prescription must be followed.
- Vulvar itching, burning, and discharge are not specific to candidiasis. First episodes, odor, fever, pelvic pain, bleeding, treatment failure, or frequent recurrence call for clinical diagnosis.
- Local burning, irritation, or discomfort can occur, although systemic exposure is lower than with oral azoles. A vaginal product and any accompanying external cream may have different application sites.
- During pregnancy, oral fluconazole should not be self-administered and a locally administered azole regimen should follow professional advice. Applicator use and treatment duration should also follow pregnancy-specific and product instructions.
What the research actually shows
Hughes and Kriedman randomized 26 women with clinically and mycologically confirmed disease under double masking to one 500-mg clotrimazole vaginal tablet or placebo. Among evaluable participants, nine of ten clotrimazole recipients had clinical and mycological clearance at one month, while all 13 placebo recipients failed at the first follow-up. Fleury and colleagues compared a single 500-mg dose with two 100-mg tablets daily for three days in a 103-participant double-blind trial; early clearance was 90% and 89%, and later success was 75% and 72%. In 2016, Zhou and colleagues found that two 500-mg doses in 240 patients with severe infection produced short-term clinical and mycological cure similar to two 150-mg doses of fluconazole, but this did not further establish placebo superiority for a single uncomplicated regimen. A human monthly-suppression trial in recurrent disease also exists, so that subclaim is limited C rather than no-evidence question mark.
Why this is classified as B (68)
The placebo-controlled trial had only 23 evaluable participants, but clinical and mycological cure separated clearly at nine of ten versus none of 13. A 103-participant double-blind regimen trial and later active-controlled studies confirmed cure. Direct endpoints and large separation are strengths, while old small placebo evidence and modern concentration in noninferiority or active-comparator studies limit the grade to B with 68 points. Local irritation, pregnancy, misdiagnosis, and management of complicated infection remain separate safety issues.
Counterpoint. Label-directed short treatment is reasonable for a familiar uncomplicated episode, but symptoms that do not improve or recur within two months warrant examination and possibly microscopy or culture rather than repeated self-treatment. Recurrent or non-albicans Candida can require a longer or different strategy.
Rejudgment record. New verdict — Applied B because clinical and mycological cure of uncomplicated vulvovaginal candidiasis was directly established in a placebo-controlled trial and replicated in active-controlled trials, while pivotal placebo evidence was very small and old and modern evidence was concentrated in noninferiority or active-comparator designs
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Clinical and mycological cure of uncomplicated vulvovaginal candidiasis | B | Direct placebo-controlled cure and repeated active-comparator evidence agree, but the pivotal placebo trial is small and old. |
| Monthly long-term suppression of recurrent vulvovaginal candidiasis | C | A small old placebo-controlled human trial exists, so evidence is not absent, but symptom suppression was limited and fungal recolonization remained common. |
| Two-dose clotrimazole treatment for severe vulvovaginal candidiasis | C | A 240-participant active-comparator trial found similarity to fluconazole, but it is a single noninferiority-type study distinct from uncomplicated single-dose treatment. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Hughes D, Kriedman T. 1984 | Prospective randomized double-blind placebo-controlled trial | 23 | Inadequately reported | Clinical and mycological cure at approximately one week and one month | At one month, nine of ten clotrimazole recipients were clinically and mycologically clear, while all 13 placebo recipients failed at first follow-up. | Direct placebo-controlled cure evidence but very small |
| Fleury F et al. 1985 | Multicenter double-blind active regimen-comparison trial | 103 | Inadequately reported; product-regimen evaluation context | Clinical and mycological clearance at 5 to 10 days and treatment success after at least 27 days | Early clearance was 90% with one 500-mg dose and 89% with the three-day 100-mg regimen; later success was 75% and 72%. | Direct evidence of efficacy across regimens |
| Zhou X et al. 2016 | Randomized active-controlled trial | 240 | Funding source not stated in the PubMed abstract | Clinical and mycological cure at 7 to 14 and 30 to 35 days | Two 500-mg clotrimazole doses produced short-term clinical and mycological cure similar to two 150-mg fluconazole doses. | Supportive active-controlled evidence in severe infection |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Clotrimazole vaginal tablet x cure of uncomplicated vulvovaginal candidiasis — Evidence Grade B·68. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/clotrimazole-vaginal-tablet-uncomplicated-vulvovaginal-candidiasis-cure/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.